- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492. PMID:303 50310.
- Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, et al. Five-year overall survival for patients with advanced non small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study. J Clin Oncol 2019;37(28):2518–2527. doi:https://doi.org/10.1200/jco.19.00934. PMID: 31154919.
- Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 2018;36(17):1675–1684. doi:https://doi.org/10.1200/jco.2017.77.0412. PMID:29570421.
- Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Janne PA, Johnson BE. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 2016;11(4):556–565. doi:https://doi.org/10.1016/j.jtho.2015.12.103. PMID:26724471.
- Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9(2):237–249. doi:https://doi.org/10.1111/j.1538-7836.2010.04131.x. PMID:21040448.
- Du G, Yang Y, Zhang Y, Sun T, Liu W, Wang Y, Li J, Zhang H. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2013;71(4):893–904. doi:https://doi.org/10.1007/s00280-013-2080-6. PMID:23355038.
- Tomita M, Shimizu T, Ayabe T, Onitsuka T. Prognostic significance of the combined use of preoperative platelet count and serum carcinoembryonic antigen level in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2010;58(11):573–576. doi:https://doi.org/10.1007/s11748-010-0647-2. PMID:21069496.
- Wang YH, Kang JK, Zhi YF, Zhang Y, Wang ZQ, Zhou Q, Niu WY, Ma MJ. The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: A systematic review and meta-analysis. Int J Surg 2018;53:304–311. doi:https://doi.org/10.1016/j.ijsu.2018.03.084. PMID:29654963.
- Wang YH, Deng SJ, Yang YD, Yao N, Zhao JM, Min GT, Wang J, Xu TF, Zhao PY, Wang HP, et al. The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Biomark Med 2017;11(2):195–210. doi:https://doi.org/10.2217/bmm-2016-0214. PMID:28097884.
- Zhuo Y, Lin L, Zhang M. Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis. Platelets 2017;28(6):560–566. doi:https://doi.org/10.1080/09537104.2016.1246712. PMID:27848258.
- Ye Q, Cheng J, Ye M, Liu D, Zhang Y. Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol 2019;30(1):e5. doi:https://doi.org/10.3802/jgo.2019.30.e5. PMID:30479089.
- Rachidi S, Kaur M, Lautenschlaeger T, Li Z. Platelet count correlates with stage and predicts survival in melanoma. Platelets 2019;30(8):1042–1046. doi:https://doi.org/10.1080/09537104.2019.1572879. PMID:30759042.
- Ohuchi M, Inoue S, Ozaki Y, Ueda K. Platelet count and mean platelet volume are associated with not only bone, soft tissue, and lymph node metastases but also with malignant pleural effusion in lung cancer patients. Neoplasma 2017;64(1):140–147. doi:https://doi.org/10.4149/neo_2017_118. PMID:27881016.
- Hong X, Xu Q, Yang Z, Wang M, Yang F, Gao Y, Zhou F, Wang L, Liu B, Chen G. The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients. Clin Respir J 2018;12(2):433–447. doi:https://doi.org/10.1111/crj.12534. PMID: 27460525.
- Holgersson G, Bergqvist M, Nilsson J, Thureson M, Harmenberg J, Bergstrom S. The prognostic value of pre-treatment leukocytosis in patients with previously treated, stage IIIB/IV non-small cell lung cancer treated with the IGF-1R pathway modulator AXL1717 or docetaxel; a retrospective analysis of a Phase II trial. Asian Pac J Cancer Prev 2017;18(6):1555–1560. doi:https://doi.org/10.22034/apjcp.2017.18.6.1555. PMID:28669167.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. doi:https://doi.org/10.1136/bmj.b2700. PMID:19622552.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603–605. doi:https://doi.org/10.1007/s10654-010-9491-z. PMID:20652370.
- Cox G, Walker RA, Andi A, Steward WP, O’Byrne KJ. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 2000;29(3):169–177. doi:https://doi.org/10.1016/s0169-5002(00)00124-0. PMID:10996419.
- Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, Sekine Y, Yoshida S, Hiroshima K, Fujisawa T. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002;35(1):29–34. doi:https://doi.org/10.1016/s0169-5002(01)00285-9. PMID: 11750710.
- Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O’Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21(3):473–482. doi:https://doi.org/10.1200/jco.2003.11.132. PMID:12560438.
- Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M, Tanimoto M. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004;71(2):170–173. doi:https://doi.org/10.1159/000076679. PMID:15031573.
- Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of north central cancer treatment group trials. Cancer 2006;107(4):781–792. doi:https://doi.org/10.1002/cncr.22049. PMID:16847887.
- Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatipoglu ON, Caglar T. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007;19(7):494–498. doi:https://doi.org/10.1016/j.clon.2007.04.002. PMID: 17513096.
- Holgersson G, Sandelin M, Hoye E, Bergström S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Holgersson M, et al. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol 2012;29(5):3176–3182. doi:https://doi.org/10.1007/s12032-012-0247-3. PMID:22565809.
- Liu HB, Gu XL, Ma XQ, Lv TF, Wu Y, Xiao YY, Yuan DM, Li YF, Song Y. Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. Neoplasma 2013;60(2):203–208. doi:https://doi.org/10.4149/neo_2013_027. PMID: 23259790.
- Maráz A, Furák J, Varga Z, Kahán Z, Tiszlavicz L, Hideghéty K. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res 2013;33(4):1725–1729. PMID:23564823.
- Kim KH, Park TY, Lee JY, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Yang SC. Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci 2014;29(4):507–511. doi:https://doi.org/10.3346/jkms.2014.29.4.507. PMID:24753697.
- Boddu P, Villlines D, Aklilu M. Paraneoplastic leukocytosis and thrombocytosis as prognostic biomarkers in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2016;19(11):725–730. doi:https://doi.org/10.3779/j..1009-3419.2016.11.02. PMID:27866514.
- Gotfrit J, Zhang T, Zanon-Heacock S, Wheatley-Price P. Patients with advanced non-small cell lung cancer requiring inpatient medical oncology consultation: characteristics, referral patterns, and outcomes. Clin Lung Cancer 2016;17(4):292–300. doi:https://doi.org/10.1016/j.cllc.2015.12.011. PMID:26837473.
- Holgersson G, Bergstrom S, Hallqvist A, Liv P, Nilsson J, Willen L, Nyman J, Ekman S, Henriksson R, Bergqvist M. The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy. Neoplasma 2017;64(6):909–915. doi:https://doi.org/10.4149/neo_2017_614. PMID: 28895417.
- Lee S, Eo W, Jeon H, Park S, Chae J. Prognostic significance of host-related biomarkers for survival in patients with advanced non-small cell lung cancer. J Cancer 2017;8(15):2974–2983. doi:https://doi.org/10.7150/jca.20866. PMID:28928889.
- Gong J, Xu L, Li Z, Hu X, Liu J, Teng Y, Jin B, Zhao M, Shi J, Guo T, et al. A clinical prognostic score to predict survival of advanced or metastatic non-small cell lung cancer (NSCLC) patients receiving first-line chemotherapy: a retrospective analysis. Med Sci Monit 2018;24:8264–8271. doi:https://doi.org/10.12659/msm.911026. PMID:30446633.
- Sakin A, Yasar N, Arici S, Demir C, Geredeli C, Aksaray F, Isik S, Cihan S. Effect of pretreatment platelet parameters on survival in limited disease small cell lung cancer. Asian Pac J Cancer Prev 2019;20(6):1879–1885. doi:https://doi.org/10.31557/apjcp.2019.20.6.1879. PMID: 31244313.
- Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C, Cihan S. The relation between hemogram parameters and survival in extensive-stage small cell lung cancer. Oncol Res Treat 2019;42(10):506–515. doi:https://doi.org/10.1159/000501595. PMID:31336378.
- Hoffmann M, Reitz D, Taugner J, Roengvoraphoj O, Käsmann L, Eze C, Karin M, Belka C, Manapov F. Blood parameters demonstrating a significant survival impact in patients with locally advanced NSCLC undergoing definitive chemoradiotherapy. Anticancer Res 2020;40(4):2319–2322. doi:https://doi.org/10.21873/antica-nres.14198. PMID:32234932.
- Łochowski M, Chałubińska-Fendler J, Łochowska B, Zawadzka I, Brzeziński D, Rębowski M, Kozak J. Prognostic value of red blood cell distribution width-standard deviation (RDW-SD) in patients operated on due to non-small cell lung cancer. J Thorac Dis 2020;12(3):773–781. doi:https://doi.org/10.21037/jtd.2019.12.94. PMID:32274144.
- Kim M, Chang H, Yang HC, Kim YJ, Lee CT, Lee JH, Jheon S, Kim K, Chung JH, Lee JS. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol 2014;12:37. doi:https://doi.org/10.1186/1477-7819-12-37. PMID:24520974.
- Zhang T, Jiang Y, Qu X, Shen H, Liu Q, Du J. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. PLoS One 2014;9(10):e111494. doi:https://doi.org/10.1371/journal.pone.0111494. PMID:25360716.
- Ji Y, Sheng L, Du X, Qiu G, Su D. Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients. Platelets 2015;26(2):138–142. doi:https://doi.org/10.3109/09537104.2014.888547. PMID:24679181.
- Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu J, Yue D, Zhang B, Wang C. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PloS One 2015;10(5):e0126496. doi:https://doi.org/10.1371/journal.pone.0126496. PMID: 25950176.
- Gao L, Zhang H, Zhang B, Zhang L, Wang C. Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer. Oncotarget 2017;8(9):15632–15641. doi:https://doi.org/10.18632/oncotarget.14921. PMID: 28152504.
- Wang YQ, Zhi QJ, Wang XY, Yue DS, Li K, Jiang RC. Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer. Oncol Lett 2017;14(4):4331–4338. doi:https://doi.org/10.3892/ol.2017.6660. PMID: 28943947.
- Liu W, Ha M, Yin N. Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer. Oncotarget 2017;8(42):73198–73207. doi:https://doi.org/10.18632/oncotarget.18336. PMID:29069863.
- Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Preoperative plateletcrit is a prognostic biomarker for survival in patients with non-small cell lung cancer. J Cancer 2020;11(10):2800–2807. doi:https://doi.org/10.7150/jca.41122. PMID:32226498.
- Liu C, Zhang H, Qi Q, Zhang B, Yue D, Wang C. The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer. Thoracic Cancer 2020;11(4):918–927. doi:https://doi.org/10.1111/1759-7714.13340. PMID:32061027.
- Li Y, Miao LY, Xiao YL, Cai HR, Zhang DP. Elevated platelets enhance cancer cell migration, promote hematogenous metastasis and associate with a poor prognosis in advanced non-small cell lung cancer cases. Asian Pac J Cancer Prev 2014;15(1):139–143. doi:https://doi.org/10.7314/apjcp.2014.15.1.139. PMID:24528015.
- Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X, Shi X, Song Y. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer 2015;6(3):275–287. doi:https://doi.org/10.1111/1759-7714.12178. PMID:26273373.
- Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, Kim SJ, Lee SH. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PloS One 2018;13(7):e0200341. doi:https://doi.org/10.1371/journal.pone.0200341. PMID:30005083.
- Hou C, Jiang F, Ma H, Zhu Q, Wang Z, Zhao B, Xue T, Tan S, Yang R, Qian Y, et al. Prognostic role of preoperative platelet, fibrinogen, and D-dimer levels in patients with non-small cell lung cancer: A multicenter prospective study. Thorac Cancer 2019;10(2):304–311. doi:https://doi.org/10.1111/1759-7714.12956. PMID:30609303.
- Sakin A, Secmeler S, Arici S, Geredeli C, Yasar N, Demir C, Aksaray F, Cihan S. Prognostic significance of mean platelet volume on local advanced non-small cell lung cancer managed with chemoradiotherapy. Sci Rep 2019;9(1):3959. doi:https://doi.org/10.1038/s41598-019-40589-4. PMID:30850724.
- Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338(17):1169–1173. doi:https://doi.org/10.1056/nejm199804233381701. PMID:9554856.
- Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther 2016;157:112–119. doi:https://doi.org/10.1016/j.pharmthera.2015.11.005. PMID:26615781.
- Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3(7):425–430. doi:https://doi.org/10.1016/s1470-2045(02)00789-1. PMID:12142172.
- Guo Y, Cui W, Pei Y, Xu D. Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway. Gynecol Oncol 2019;153(3):639–650. doi:https://doi.org/10.1016/j.ygyno.2019.02.026. PMID:30928020.
- Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol 2012;189(1):154–160. doi:https://doi.org/10.4049/jimmunol.1103194. PMID:22649191.
- Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 2014;33(1):231–269. doi:https://doi.org/10.1007/s10555-014-9498-0. PMID:24696047.
- Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev 2017;36(2):249–262. doi:https://doi.org/10.1007/s10555-017-9673-1. PMID:28681240.
- Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. Platelets 2015;26(3):199–211. doi:https://doi.org/10.3109/09537104.2014.909022. PMID: 24832135.
Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis
View further author information
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.